Mitsubishi UFJ Trust & Banking Corp Decreases Stock Holdings in Zoetis Inc. $ZTS

Mitsubishi UFJ Trust & Banking Corp decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 22.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 228,655 shares of the company’s stock after selling 66,827 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Zoetis were worth $28,769,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. CIBC Asset Management Inc raised its stake in shares of Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after acquiring an additional 10,434 shares during the period. Nordea Investment Management AB raised its stake in shares of Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares during the period. Seilern Investment Management Ltd raised its stake in shares of Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock valued at $41,957,000 after acquiring an additional 261,155 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Zoetis by 134.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock valued at $205,290,000 after acquiring an additional 935,432 shares during the period. Finally, Ninety One UK Ltd raised its stake in shares of Zoetis by 19.6% in the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after acquiring an additional 183,686 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 2.3%

NYSE ZTS opened at $113.97 on Thursday. The company’s 50-day moving average price is $120.17 and its 200-day moving average price is $124.86. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a market cap of $47.94 billion, a PE ratio of 18.93, a PEG ratio of 1.80 and a beta of 0.98. Zoetis Inc. has a 12 month low of $112.97 and a 12 month high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts forecast that Zoetis Inc. will post 7.02 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. Zoetis’s dividend payout ratio is presently 35.22%.

Analysts Set New Price Targets

ZTS has been the topic of several recent analyst reports. Citigroup initiated coverage on shares of Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 target price on the stock. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, UBS Group reduced their target price on shares of Zoetis from $136.00 to $130.00 and set a “neutral” rating on the stock in a research note on Tuesday. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zoetis presently has a consensus rating of “Hold” and an average price target of $151.75.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.